- $22.18m
- $19.64m
- 14
- 19
- 53
- 18
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.51 | ||
| Price to Tang. Book | 2.61 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -111.71% | ||
| Return on Equity | -99.84% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | 3 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
NanoViricides, Inc. is a clinical-stage company that is creating special purpose nanomaterials for antiviral therapy. Its nanoviricide class of drug candidates and the nanoviricide technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. Its lead drug candidate is NV-387, a broad-spectrum antiviral drug that it plans to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. It is focused on advancing NV-387 into Phase II human clinical trials. Its other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. NV-CoV-2 (API NV-387) is its nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is its other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. It has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.
Directors
- Anil Diwan CHM (63)
- Meeta Vyas CFO (63)
- Stanley Glick IND (85)
- Makarand Jawadekar IND (70)
- Theodore Rokita IND (51)
- Brian Zucker IND (59)
- Last Annual
- June 30th, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- April 1st, 2005
- Public Since
- August 12th, 2004
- No. of Shareholders
- 146
- No. of Employees
- 7
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NYSE MKT- Shares in Issue
- 16,072,000
- Address
- 1 Controls Drive, SHELTON, 06484
- Web
- https://www.nanoviricides.com/
- Phone
- +1 2039376137
- Auditors
- EisnerAmper LLP
Latest News for NNVC
Upcoming Events for NNVC
Q4 2025 NanoViricides Inc Earnings Release
Q1 2026 NanoViricides Inc Earnings Release
NanoViricides Inc Annual Shareholders Meeting
Similar to NNVC
Actinium Pharmaceuticals
NYSE MKT
Aeon Biopharma
NYSE MKT
AIM ImmunoTech
NYSE MKT
Apimeds Pharmaceuticals US
NYSE MKT
Armata Pharmaceuticals
NYSE MKT
FAQ
As of Today at 22:11 UTC, shares in NanoViricides are trading at $1.38. This share price information is delayed by 15 minutes.
Shares in NanoViricides last closed at $1.38 and the price had moved by -21.59% over the past 365 days. In terms of relative price strength the NanoViricides share price has underperformed the S&P500 Index by -29.9% over the past year.
The overall consensus recommendation for NanoViricides is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreNanoViricides does not currently pay a dividend.
NanoViricides does not currently pay a dividend.
NanoViricides does not currently pay a dividend.
To buy shares in NanoViricides you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $1.38, shares in NanoViricides had a market capitalisation of $22.18m.
Here are the trading details for NanoViricides:
- Country of listing: United States
- Exchange: ASQ
- Ticker Symbol: NNVC
Based on an overall assessment of its quality, value and momentum NanoViricides is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in NanoViricides is $6.50. That is 371.01% above the last closing price of $1.38.
Analysts covering NanoViricides currently have a consensus Earnings Per Share (EPS) forecast of -$0.57 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like NanoViricides. Over the past six months, its share price has underperformed the S&P500 Index by -11.72%.
As of the last closing price of $1.38, shares in NanoViricides were trading +0.91% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The NanoViricides PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.38.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
NanoViricides' management team is headed by:
- Anil Diwan - CHM
- Meeta Vyas - CFO
- Stanley Glick - IND
- Makarand Jawadekar - IND
- Theodore Rokita - IND
- Brian Zucker - IND